Design, synthesis and immunological evaluation of monophosphoryl lipid A derivatives as adjuvants for a RBD-hFc based SARS-CoV-2 vaccine

• Published in: MedChemComm Vol. 14; no. 1; pp. 47 - 55
• Main Authors: Su, Shiwei, Chen, Liqing, Yang, Menglan, Liang, Dan, Ke, Bixia, Liu, Zhongqiu, Ke, Changwen, Liao, Guochao, Liu, Liang, Luo, Xiang
• Format: Journal Article
• Language: English
• Published: CAMBRIDGE Royal Soc Chemistry 25.01.2023; Royal Society of Chemistry; RSC
• Subjects: Adjuvants; Biochemistry & Molecular Biology; Biological activity; Biological effects; Chemistry; Chemistry, Medicinal; COVID-19; E coli; Functional groups; Hydrofluorocarbons; Immune response; Immunological enhancement; Immunology; Immunotherapy; Life Sciences & Biomedicine; Lipid A; Lipids; Monophosphoryl lipid A; Pharmacology & Pharmacy; Science & Technology; Severe acute respiratory syndrome coronavirus 2; TLR4 protein; Toll-like receptors; Vaccines; ACTIVATION; ACID; PROTEIN; ANALOGS

Toll-like receptor 4 (TLR4) is a reliable target for the development of vaccine adjuvants. To identify novel TLR4 ligands with improved immunological properties for use as adjuvants for a RBD-hFc based SARS-CoV-2 vaccine, herein, natural E. coli monophosphoryl lipid A (MPLA) and nine of its derivati...